• Executive Summary
o Market Overview
• Market Landscape
o Market ecosystem
o Market characteristics
o Value chain analysis
• Market Sizing
o Market definition
o Market segment analysis
o Market size 2019
o Market outlook: Forecast for 2019 – 2024
• Five Forces Analysis
o Five forces summary
o Bargaining power of buyers
o Bargaining power of suppliers
o Threat of new entrants
o Threat of substitutes
o Threat of rivalry
o Market condition
• Market Segmentation by Technology
o Market segments
o Comparison by Technology
o CTC and ctDNA – Market size and forecast 2019-2024
o Exosome and RNA – Market size and forecast 2019-2024
o Market opportunity by Technology
• Customer landscape
• Geographic Landscape
o Geographic segmentation
o Geographic comparison
o North America – Market size and forecast 2019-2024
o Europe – Market size and forecast 2019-2024
o Asia – Market size and forecast 2019-2024
o ROW – Market size and forecast 2019-2024
o Key leading countries
o Market opportunity by geography
o Market drivers
o Market challenges
o Market trends
• Vendor Landscape
o Overview
o Vendor landscape
o Landscape disruption
• Vendor Analysis
o Vendors covered
o Market positioning of vendors
o ANGLE Plc
o Biocept Inc.
o Bio-Techne Corp.
o CIRCULOGENE
o F. Hoffmann-La Roche Ltd.
o Guardant Health Inc.
o LungLife AI Inc.
o Myriad Genetics Inc.
o QIAGEN NV
o SAGA Diagnostics AB
• Appendix
o Scope of the report
o Currency conversion rates for US$
o Research methodology
o List of abbreviations
Exhibit
• 1: Key Finding 1
• 2: Key Finding 2
• 3: Key Finding 3
• 4: Key Finding 5
• 5: Key Finding 6
• 6: Key Finding 7
• 7: Key Finding 8
• 8: Parent market
• 9: Market characteristics
• 10: Offerings of vendors included in the market definition
• 11: Market segments
• 12: Global – Market size and forecast 2019 – 2024 ($ million)
• 13: Global market: Year-over-year growth 2019 – 2024 (%)
• 14: Five forces analysis 2019 & 2024
• 15: Bargaining power of buyers
• 16: Bargaining power of suppliers
• 17: Threat of new entrants
• 18: Threat of substitutes
• 19: Threat of rivalry
• 20: Market condition – Five forces 2019
• 21: Technology – Market share 2019-2024 (%)
• 22: Comparison by Technology
• 23: CTC and ctDNA – Market size and forecast 2019-2024 ($ million)
• 24: CTC and ctDNA – Year-over-year growth 2019-2024 (%)
• 25: Exosome and RNA – Market size and forecast 2019-2024 ($ million)
• 26: Exosome and RNA – Year-over-year growth 2019-2024 (%)
• 27: Market opportunity by Technology
• 28: Customer landscape
• 29: Market share by geography 2019-2024 (%)
• 30: Geographic comparison
• 31: North America – Market size and forecast 2019-2024 ($ million)
• 32: North America – Year-over-year growth 2019-2024 (%)
• 33: Europe – Market size and forecast 2019-2024 ($ million)
• 34: Europe – Year-over-year growth 2019-2024 (%)
• 35: Asia – Market size and forecast 2019-2024 ($ million)
• 36: Asia – Year-over-year growth 2019-2024 (%)
• 37: ROW – Market size and forecast 2019-2024 ($ million)
• 38: ROW – Year-over-year growth 2019-2024 (%)
• 39: Key leading countries
• 40: Market opportunity by geography ($ million)
• 41: Impact of drivers and challenges
• 42: Vendor landscape
• 43: Landscape disruption
• 44: Industry risks
• 45: Vendors covered
• 46: Market positioning of vendors
• 47: ANGLE Plc – Overview
• 48: ANGLE Plc – Business segments
• 49: ANGLE Plc – Key offerings
• 50: ANGLE Plc – Key customers
• 51: ANGLE Plc – Segment focus
• 52: Biocept Inc. – Overview
• 53: Biocept Inc. – Business segments
• 54: Biocept Inc. – Key offerings
• 55: Biocept Inc. – Key customers
• 56: Biocept Inc. – Segment focus
• 57: Bio-Techne Corp. – Overview
• 58: Bio-Techne Corp. – Business segments
• 59: Bio-Techne Corp. – Key offerings
• 60: Bio-Techne Corp. – Key customers
• 61: Bio-Techne Corp. – Segment focus
• 62: CIRCULOGENE – Overview
• 63: CIRCULOGENE – Product and service
• 64: CIRCULOGENE – Key offerings
• 65: CIRCULOGENE – Key customers
• 66: CIRCULOGENE – Segment focus
• 67: F. Hoffmann-La Roche Ltd. – Overview
• 68: F. Hoffmann-La Roche Ltd. – Business segments
• 69: F. Hoffmann-La Roche Ltd. – Key offerings
• 70: F. Hoffmann-La Roche Ltd. – Key customers
• 71: F. Hoffmann-La Roche Ltd. – Segment focus
• 72: Guardant Health Inc. – Overview
• 73: Guardant Health Inc. – Business segments
• 74: Guardant Health Inc. – Key offerings
• 75: Guardant Health Inc. – Key customers
• 76: Guardant Health Inc. – Segment focus
• 77: LungLife AI Inc. – Overview
• 78: LungLife AI Inc. – Product and service
• 79: LungLife AI Inc. – Key offerings
• 80: LungLife AI Inc. – Key customers
• 81: LungLife AI Inc. – Segment focus
• 82: Myriad Genetics Inc. – Overview
• 83: Myriad Genetics Inc. – Business segments
• 84: Myriad Genetics Inc. – Key offerings
• 85: Myriad Genetics Inc. – Key customers
• 86: Myriad Genetics Inc. – Segment focus
• 87: QIAGEN NV – Overview
• 88: QIAGEN NV – Business segments
• 89: QIAGEN NV – Key offerings
• 90: QIAGEN NV – Key customers
• 91: QIAGEN NV – Segment focus
• 92: SAGA Diagnostics AB – Overview
• 93: SAGA Diagnostics AB – Product and service
• 94: SAGA Diagnostics AB – Key offerings
• 95: SAGA Diagnostics AB – Key customers
• 96: SAGA Diagnostics AB – Segment focus
• 97: Currency conversion rates for US$
• 98: Research Methodology
• 99: Validation techniques employed for market sizing
• 100: Information sources
• 101: List of abbreviations
【掲載企業】
ANGLE Plc, Biocept Inc., Bio-Techne Corp., CIRCULOGENE, F. Hoffmann-La Roche Ltd., Guardant Health Inc., LungLife AI Inc., Myriad Genetics Inc., QIAGEN NV, SAGA Diagnostics AB
【免責事項】
https://www.marketreport.jp/reports-disclaimer